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Clostridium difﬁ  cile is a recognized pathogen in neo-
natal pigs and may contribute to enteritis in calves. Toxino-
type V strains have been rare causes of human C. difﬁ  cile–
associated disease (CDAD). We examined toxinotype V 
in human disease, the genetic relationship of animal and 
human toxinotype V strains, and in vitro toxin production of 
these strains. From 2001 through 2006, 8 (1.3%) of 620 pa-
tient isolates were identiﬁ  ed as toxinotype V; before 2001, 
7 (<0.02%) of ≈6,000 isolates were identiﬁ  ed as toxinotype 
V. Six (46.2%) of 13 case-patients for whom information 
was available had community-associated CDAD. Molecular 
characterization showed a high degree of similarity between 
human and animal toxinotype V isolates; all contained a 39-
bp tcdC deletion and most produced binary toxin. Further 
study is needed to understand the epidemiology of CDAD 
caused by toxinotype V C. difﬁ  cile, including the potential of 
foodborne transmission to humans.
R
ecent evidence suggests that the epidemiology of 
Clostridium difﬁ  cile–associated disease (CDAD) is in-
creasing in incidence and severity (1–3). These changes are 
due, at least in part, to the emergence of a more virulent C. 
difﬁ  cile strain, designated NAP1 (based on its pulsed-ﬁ  eld 
gel electrophoresis [PFGE] pattern), BI (by restriction en-
donuclease analysis [REA]), toxinotype III (by PCR char-
acterization of the pathogenicity locus), and 027 (by PCR 
ribotyping) (4).  However, the emergence of BI/NAP1/027 
may not be solely responsible for changes in CDAD epide-
miology, and the origin of this and other virulent strains is 
still largely unknown. C. difﬁ  cile has also recently emerged 
as a pathogen or commensal in food animals such as neo-
natal pigs and beef and dairy calves (5–7); most of these 
animal isolates are toxigenic. Although several ribotypes 
have been identiﬁ  ed in calves, the predominant ribotype in 
both calves and pigs is a toxinotype V strain (8,9). More-
over, recent reports suggest that C. difﬁ  cile strains recog-
nized as causes of human disease may contaminate retail 
meats (10).
To better understand whether food sources could be a 
source of infection for humans, we investigated recent and 
past human CDAD caused by toxinotype V C. difﬁ  cile and 
compared isolates from these cases with those recovered 
from neonatal pigs and calves. We documented apparent 
changes in the frequency with which these toxinotype V 
strains cause human CDAD and compared the molecular 
characterization and toxin production of these strains with 
those of recent epidemic (i.e., BI/NAP1/027) and nonepi-
demic isolates.
Materials and Methods
Human Case Finding and Deﬁ  nitions
Case ﬁ  nding was performed by reviewing recent and 
past human isolates of interest from 2 sources. Cases were 
deﬁ  ned as patients with clinical isolates identiﬁ  ed as toxi-
notype V by analysis of restriction fragment length poly-
morphisms (RFLPs) of toxin-encoding genes. First, we 
reviewed 620 C. difﬁ  cile human isolates sent to the Centers 
for Disease Control and Prevention (CDC) from healthcare 
facilities and health departments in multiple states during 
hospital-associated outbreaks reported from 2001 through 
early 2007. Second, we reviewed a database of >6,000 iso-
lates maintained by the Hines Veterans Affairs (VA) Hospi-
tal, representing CDAD reported from multiple healthcare 
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facilities from 1984 up to January 1, 2001. All toxinotype 
V isolates were obtained from patients with a diagnosis of 
CDAD based on clinical history (e.g., diarrhea) and a posi-
tive clinical laboratory test for C. difﬁ  cile toxin (e.g., cyto-
toxin assay or enzyme immunoassay).
Isolates identiﬁ  ed from the Hines VA Hospital data-
base were designated “past,” and isolates sent from hospi-
tals to CDC from 2001 through early 2007 were designated 
“recent.” Additional clinical information was obtained for 
recent case-patients from a standard reporting form com-
pleted by the original submitting institutions. The propor-
tions of past and recent isolates identiﬁ  ed as toxinotype V 
were compared with the χ2 test results by using SPSS ver-
sion 13.0 (SPSS, Inc., Chicago, IL, USA).
Case-patients were categorized with regard to likely 
place of acquisition according to recommendations devel-
oped by the Clostridium difﬁ  cile Surveillance Working 
Group (11). Cases of CDAD were considered community-
associated (CA-CDAD) if symptom onset (or positive C. 
difﬁ  cile toxin test) occurred within <48 h after the patient 
was admitted to a healthcare facility, provided that it had 
been >12 weeks since the patient was last discharged from 
a healthcare facility. Cases of CDAD were considered 
healthcare facility–associated CDAD (HCFA-CDAD) if 
the patient had symptom onset >48 h after admission to 
a healthcare facility or was discharged from a healthcare 
facility within the previous 4 weeks. Cases were classiﬁ  ed 
as indeterminate if symptom onset was within <48 h of a 
patient’s admission to a healthcare facility and 4–12 weeks 
since discharge from a previous admission. Case-patients 
were considered exposed to antimicrobial agents if the pa-
tient received a dose of any antimicrobial agent within the 
30 days before symptom onset.
Laboratory Methods
C. difﬁ  cile isolates from humans and animals with 
clinical disease were obtained from diagnostic laboratories 
as previously described (4,8). Swine isolates were obtained 
from neonatal pigs with CDAD in North Carolina, Iowa, 
Texas, Utah, Ohio, and Arizona from 1999 to 2005. Bovine 
strains were isolated from January 1, 2003, through 2005, 
mainly from diarrheic Holstein calves 1 day to 6 weeks 
of age, originating in southern California, Arizona, New 
Mexico, Nevada, Texas, and Utah and maintained in pre-
feedlot housing in calf ranches in Arizona. Domestic ani-
mal isolates were selected for study on the basis of host of 
origin, date of isolation, and geographic origin, all of which 
were independent. All food animal and human isolates 
were typed by PFGE with SmaI digestion as previously de-
scribed (12,13) and analyzed with BioNumerics software 
version 4.01 (Applied Maths, Austin, TX, USA). Repeat 
PFGE analysis was performed with EagI-digested DNA 
if human–food animal isolate pairs were indistinguishable 
when subjected to PFGE after digestion with SmaI or when 
SmaI digestion yielded too few bands for analysis. REA 
typing was performed, and patterns were compared as pre-
viously described (12). RFLP analysis of PCR fragments 
A3 and B1, from within tcdA and tcdB, respectively, was 
performed as previously described to determine toxino-
types (14).
PCR was used to detect cdtB, one of the genes encod-
ing binary toxin. Deletions in tcdC were detected by PCR 
with primers tcdc1 and tcdc2, as described (15).
A subset of toxinotype V animal isolates (7 bovine, 7 
porcine) and 7 recent human isolates were selected for toxin 
quantiﬁ  cation. Production of toxins A and B was measured 
by ELISA as previously described (1). Toxin production 
was measured at 24 h, 48 h, and 72 h, and cell growth at 24 
h and 48 h. Cell growth and in vitro toxin A and B produc-
tion were compared between combined animal and human 
isolates of toxinotype V to human epidemic strain isolates 
(i.e., BI/NAP1/027; toxinotype III), and recent nonepi-
demic human strains (toxinotype 0) (1). Cell growth was 
compared by using the Student t test; the Mann-Whitney 
test was used to compare toxin production because toxin 
production values were not normally distributed.
Fourteen human (7 recent, 7 past) and 16 animal (8 
bovine, 8 porcine) toxinotype V isolates were randomly 
selected for antimicrobial drug susceptibility testing. Sus-
ceptibility to clindamycin, levoﬂ  oxacin, moxiﬂ  oxacin, and 
gatiﬂ   oxacin was determined by using E-test strips (AB 
Biodisk, Piscataway, NJ, USA) on Brucella agar plates with 
5% sheep blood (Remel, Lenexa, KS, USA). Results were 
interpreted according to Clinical and Laboratory Standards 
Institute standard criteria (16). However, because no break-
points have been established for levoﬂ  oxacin and gatiﬂ  oxa-
cin, moxiﬂ  oxacin breakpoints were used for interpretation 
of these results.
Results
Human Cases
Seven past cases of human infection with toxinotype 
V C. difﬁ  cile were identiﬁ  ed among the ≈6,000 human 
isolates in the Hines VA database; these cases occurred 
over 11 years before 2001. Eight additional recent cas-
es were identiﬁ  ed among the 620 human isolates sent 
to CDC from multiple states during 2001 through April 
2006. The difference in proportions of past (<0.2%) and 
recent (1.3%) isolates that were toxinotype V was statisti-
cally signiﬁ  cant (p<0.001). Three (38%) of 8 recent cases 
were CA-CDAD, 7 (88%) of such patients were exposed 
to antimicrobial agents, and 1 (13%) patient died from 
complications attributed to CDAD (Table 1). Four recent 
case-patients (50%) were male, and the median age was 71 
years. Among patients for whom records were available, 
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3 (60%) of 5 past cases were judged to be CA-CDAD and 
4 of 4 past cases were in persons exposed to antimicrobial 
agents.
Laboratory Results
All 8 recent human isolates had a 39-bp deletion in 
tcdC, and 6 (75%) of 8 were binary toxin positive. All 7 
past human isolates also had a 39-bp deletion in tcdC, and 
7 (100%) of 7 were binary toxin positive. Thirty-three toxi-
notype V animal isolates were obtained; they displayed a 
variety of PFGE patterns (Figure 1). All, however, were 
binary toxin positive and had a 39-bp deletion in tcdC. 
Three animal–human isolate groups had indistinguishable 
PFGE patterns (100% similarity) when digestion was per-
formed with the SmaI enzyme. The ﬁ  rst group contained 1 
human isolate (REA subtype BK1) that was indistinguish-
able by PFGE (NAP7) from 1 porcine isolate (REA sub-
type BK13). The second group consisted of 5 human and 
2 porcine isolates, all of which were designated NAP7 by 
PFGE, although REA demonstrated 4 different subtypes. 
The third group contained 1 human isolate and 2 porcine 
isolates, which were indistinguishable by PFGE and REA 
(NAP8 and BK6). The 9 isolates in groups 1 and 2 were 
only 80% similar when digestion was performed with EagI. 
However, the isolates in the third group were 95% similar, 
and 1 porcine isolate was indistinguishable (100% similar-
ity) from 1 human isolate, even after digestion with EagI.
Median toxin A and B production in the 21 toxino-
type V isolates analyzed (7 bovine, 7 porcine, 7 of 8 recent 
human) was greater than that by nonepidemic toxinotype 
0 isolates but less than that by epidemic toxinotype III 
isolates at all time points measured (Figure 2). The mean 
absorbance measurements at 600 nm, representing cell 
density, were measured at 24 h and 48 h and were not sig-
niﬁ  cantly different for toxinotype V isolates (1.56 and 1.06, 
respectively) than for toxinotype 0 isolates (1.77 and 1.39) 
or toxinotype III isolates (2.07 and 1.64).
Antimicrobial drug susceptibility testing was per-
formed on 14 of 15 human and 16 of 33 animal toxino-
type V isolates (Table 2). Resistance rates were similar 
overall in human and animal toxinotype V isolates except 
that more bovine isolates (88%) were susceptible to clin-
damycin than were porcine (0%, p<0.01) or human isolates 
(9%, p<0.01). All human and animal toxinotype V isolates 
(multiple strains by REA and PFGE) were susceptible to 
gatiﬂ   oxacin and moxiﬂ   oxacin, which differed markedly 
from human toxinotype III (BI/NAP1/027) and toxinotype 
0 isolates (multiple strains by REA and PFGE).
Discussion
In a review of recent and past isolates, we identiﬁ  ed 
several human cases of CDAD caused by toxinotype V 
strains of C. difﬁ  cile, which has been reported as a cause of 
epidemic disease in neonatal pigs and colonization in calves 
during the past decade (9,17,18). Moreover, different rates 
of occurrence in these temporally divergent populations 
suggest that toxinotype V may be an increasing cause of 
human CDAD, relative to other strains. The toxinotype V 
animal isolates included in our study have been previously 
identiﬁ  ed as PCR ribotype 078, the most prevalent ribotype 
among calves and pigs, accounting for 94% (bovine) and 
83% (swine) of isolates tested from multiple geographic 
regions (8). Food animal isolates we tested shared a high 
degree of similarity with human isolates, with 2 instances 
of animal–human isolate pairs appearing indistinguishable 
by REA or PFGE subtyping. In addition, all animal and 
human isolates displayed 39-bp deletions in tcdC, and most 
(45/47; 96%) were binary toxin positive.
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Table 1. Clinical epidemiology of human toxinotype V Clostridium difficile cases, 1989–2006* 
Origin Location Sex Age, y  Antimicrobial agents† Etiology  Diagnosis date  Disposition
1 R  Pennsylvania  F 75 Yes  HCFA 2001 May 2  Died
2 R  Illinois M 54 Yes  CA 2003 Jul 24  Sent home 
3 R  Iowa F 71 Yes  HCFA 2004 Jul 29  Sent home 
4 R  Texas M 56 Yes  HCFA 2004 Nov 5  Sent home 
5 R  Connecticut F 85 Yes  HCFA 2004 Nov 21  Died
6 R  Georgia  M 72 Yes  CA 2005 Feb 8  Sent home 
7 R  Connecticut F 78 No IND 2005 Jun 18  Sent home 
8 R  Massachusetts M 51 Yes  CA 2006 Jan 20  Died‡
1 P  Minnesota M NA Yes  HCFA 1989 Apr 26  Unknown 
2 P  Arizona NA NA Unknown  Unknown  1991 Unknown 
3 P  Illinois M 71 Unknown  CA 1995 Mar 28  Unknown 
4 P  Illinois M 71 Yes  HCFA 1995 Apr 5  Unknown 
5 P  Belgium NA NA Unknown  Unknown  <1996 Unknown 
6 P  Illinois M 73 Yes  CA 1999 Sep 21  Sent home 
7 P  Illinois M 60 Yes  CA 1999 Nov 24  Sent home 
*R, recent; P, past; HCFA, healthcare facility–associated; CA, community-associated; IND, indeterminate (patient with symptom onset <48 h of admission 
to healthcare facility and 4–12 wks since discharge from previous admission); NA, not available. 
†History of antimicrobial drug use within 30 d before C. difficile–associated disease (CDAD) diagnosis. 
‡Death attributed to CDAD. RESEARCH
Although C. difﬁ  cile is recognized as a cause of dis-
ease in several animal species (19–22), little investiga-
tion has been conducted on the potential for interspecies 
transmission of C. difﬁ  cile to humans. Previous studies 
have suggested the possibility of C. difﬁ  cile transmission 
between humans and domestic pets (23,24), but no inter-
species transmission has been documented, and few studies 
have examined the possible link between CDAD in food 
animals and humans. Identiﬁ   cation of the same variant 
toxinotype strain as responsible for both human and animal 
disease in our study suggests at least 3 possible causes for 
human toxinotype V CDAD: 1) exposure of humans and 
animals to a common environmental source of C. difﬁ  cile, 
2) human disease caused by transmission by means of di-
rect or indirect (e.g., through contaminated produce, water, 
or the environment) contact with infected live animals, and 
3) human disease linked to consumption of products from 
food-producing animals. Both the genetic similarity of the 
human and animal isolates in our study and the apparent 
increasing importance of toxinotype V isolates in human 
CDAD after their emergence in animals may suggest food-
borne or other forms of animal-to-human transmission.
In contrast to HCFA-CDAD, where patient-to-patient 
transmission of C. difﬁ  cile is more likely, animal contact 
is a more plausible means of transmission for CA-CDAD. 
Our results suggest that toxinotype V C. difﬁ  cile may be a 
relatively common cause of community-associated disease. 
Our results suggest that toxinotype V C. difﬁ  cile may be a 
relatively common cause of community-associated disease. 
Despite evidence that only 20% of all human CDAD cases 
are community-associated (25,26), 6 (46%) of 13 human 
toxinotype V cases in our study were identiﬁ  ed as CA-
CDAD. The high prevalence of CA-CDAD among toxi-
notype V cases we found is consistent with other studies 
that have identiﬁ  ed variant toxinotypes more frequently in 
CA-CDAD than in HCFA-CDAD (27,28).
Toxinotype V strains may also be increasing as a 
cause of human CDAD since the emergence or recognition 
of epidemic toxinotype V disease in animals. In the past, 
reported frequencies of human strains with variant toxino-
types ranged from 6.4% to 13.4% of all C. difﬁ  cile isolates 
collected (29–33), and toxinotype V strains contributed 
few cases to these frequency studies. However, a recent 
preliminary report from an Italian hospital indicated an 
upsurge in the proportion of binary toxin–positive C. dif-
ﬁ  cile strains responsible for healthcare-associated disease 
in 2002 and 2003; most of these strains were toxinotype 
V (34). Toxinotype V appears to be an important cause of 
CDAD in food-producing pigs in parts of Europe, just as it 
is in North America (35).
The epidemiology of human CDAD has been affected 
by recent increases in the incidence and severity of disease. 
These changes have been largely attributed to the emer-
gence of the BI/NAP1/027 C. difﬁ  cile strain which, like the 
toxinotype V strains described here, is a toxin gene variant 
(i.e., toxinotype III) with an 18-bp deletion in tcdC (rather 
than the 39-bp deletion observed in toxinotype V strains) 
and with genes that encode binary toxin (4). In addition 
to this 18-bp deletion, and perhaps more importantly, BI/
NAP1/027 has an upstream single nucleotide deletion at 
nucleotide position 117 (∆117), leading to a reading frame-
shift and early termination of protein translation (27).
Current literature suggests that this considerable trun-
cation of TcdC may impair its negative regulatory function 
and contribute to the increased toxin production observed 
in BI/NAP1/027 strains (27,36). Molecular analysis of toxi-
notype V C. difﬁ  cile has demonstrated a similarly truncated 
TcdC (61 aa compared with 65 aa in BI/NAP1/027 strains 
and 232 aa in wild-type TcdC) (15), which may imply 
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Figure 1. A). Dendrogram analysis of toxinotype V Clostridium difﬁ  cile 
human and animal isolates using pulsed ﬁ  eld gel electrophoresis 
(PFGE);  SmaI restriction digest. Three animal-human isolate 
groups had indistinguishable PFGE patterns (2 NAP7 and 1 NAP8 
group). Three of the NAP8 isolates (2005071, 2005093, 2005524) 
had identical REA types (BK6) as well. *PCR type unavailable. B) 
Dendrogram analysis using PFGE; EagI restriction digest. One 
human–pig pair (2005071 and 2005514) had identical PFGE 
patterns by both EagI and SmaI as well as identical REA patterns 
(BK6). Digestion of bovine isolates with EagI yielded results that 
were not interpretable and were not included in this ﬁ  gure. Toxinotype V Clostridium difﬁ  cile
hypervirulence for this strain as well. In contrast, isolates 
most commonly found in US hospitals before 2001 were 
toxinotype 0, had no polymorphisms in tcdC, and were bi-
nary toxin negative (37). Some of the increased virulence 
of BI/NAP1/027 may be due to its documented increased 
toxin A and B production in vitro (1). Although we did not 
ﬁ  nd toxin production in toxinotype V isolates similar to BI/
NAP1/027 levels, they did produce more toxin than non-
epidemic toxinotype 0 isolates at all time points. Further-
more, the range of toxin A and B levels in our toxinotype V 
isolates was wide, and a minority produced toxin at similar 
or greater levels than BI/NAP1/027 strains.
This study is subject to the following limitations. First, 
the number of toxinotype V isolates examined was small 
and may not be wholly representative of this strain as it 
manifests in human or animal disease. Furthermore, re-
cent isolates were collected from institutions that reported 
healthcare-associated outbreaks of CDAD, and clinical 
information describing patients from whom specimens 
were obtained may therefore overestimate disease severity. 
Moreover, since recent isolates were obtained from health-
care facilities that were experiencing CDAD outbreaks, 
they may represent a different population of patients than 
the past isolates, which were obtained from a variety of 
sources, some of which were ongoing clinical surveillance 
projects and some of which were outbreak investigations. 
The 2 source populations, however, can be considered rea-
sonably similar in that both represent primarily hospital-
ized patients. If, however, the recent database contains a 
substantially greater proportion of outbreak-related isolates 
than the past collection, this would only strengthen the evi-
dence for the recent emergence of toxinotype V CDAD. 
Since outbreaks of CDAD are largely associated with the 
epidemic, toxinotype III strain of C. difﬁ  cile (4), relatively 
few toxinotype V isolates should be present in a recent data-
base composed of outbreak-related isolates. The increased 
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Figure 2. In vitro toxin production 
of toxinotype V Clostridium difﬁ  cile 
isolates compared with epidemic 
toxinotype III and nonepidemic 
toxinotype 0 strains. Toxin A 
and Toxin B concentrations in 
micrograms per milliliter at 24, 
48, and 72 h are shown for 
25 toxinotype 0 isolates, 21 
toxinotype V isolates (7 human; 
14 animal), and 15 toxinotype III 
isolates. Horizontal lines indicate 
median values for each group 
and the p values are shown for 
comparison of the median toxin 
levels of toxinotype V isolates with 
toxinotype 0 and toxinotype III 
isolates.
Table 2. Antimicrobial drug susceptibility of toxinotype V Clostridium difficile isolates, 1989–2006* 
Clindamycin Levofloxacin† Moxifloxacin Gatifloxacin†
Source N S I/R Range S I/R Range S Range S Range
Human 14 2 (14)  12 (86)  2–>256 6 (43)  8 (57)  2–>32 14 (100)  0.5–1 14 (100)  0.5–1
  Recent   7 2 (29)  5 (71)  2–>256 0 7 (100) >32 7 (100)  0.5 7 (100)  0.5–1
  Past  7 0 7 (100)  4–>256 7 (100)  0 2–4 7 (100)  0.5–1 7 (100)  0.5–1
Porcine 8 0 8 (100)  4-–>256 2 (25)  6 (75) 2–>32 8 (100)  0.5–1 8 (100)  0.5–1
Bovine 8 7 (88)  1 (12)  1–4 8 (100) 0 2–4 8 (100)  0.5 8 (100)  0.5
*No. (%) Clostidium difficile isolates shown in each interpretive category. S, susceptible; I/R, intermediate or resistant. 
†Using moxifloxacin interpretive criteria. RESEARCH
prevalence of toxinotype V in recent isolates compared 
with past ones may therefore represent an underestimate of 
the true prevalence of toxinotype V C. difﬁ  cile.
Additionally, little is known about the types of C. dif-
ﬁ  cile that cause disease in animals, which makes it impos-
sible to determine whether the current toxinotype V strains 
are new or simply newly recognized. Finally, information 
about human cases is limited, particularly with respect to 
possible routes for community acquisition of disease; thus, 
evidence upon which to base conclusions regarding inter-
species transmission is limited.
Although relatively common in animal CDAD, toxino-
type V is currently an uncommon cause of human illness, 
which may occur more frequently among persons without 
traditional risk factors associated with CDAD, such as re-
cent exposure to a healthcare setting. In vitro toxin produc-
tion results from our limited sample suggest that toxinotype 
V strains have the potential to cause increased severity of 
human disease, although further studies are needed to cor-
roborate this association. Although they share similar clini-
cal features, evidence suggests that the predominant strains 
causing CDAD in humans and different animal species are 
distinct (8,38). Nonetheless, our ﬁ  nding of similarity be-
tween relatively widespread animal strains of C. difﬁ  cile 
and strains responsible for occasional human disease raises 
the possibility of interspecies transmission. Further studies 
are needed to understand the etiology of CDAD caused by 
toxinotype V C. difﬁ  cile and the mechanisms of transmis-
sion between animals and humans, including the role of the 
food supply.
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etymologia etymologia
Sapovirus
[Sap′ o-vi′′ rəs]
Sapovirus, formerly Sapporo-like virus after Sapporo, Japan, where ﬁ  rst recognized during an outbreak in an 
orphanage in 1977. A genus of viruses of the family Caliciviridae, they cause self-limited, acute foodborne 
gastroenteritis. Morphologically similar viruses were detected in a subsequent series of outbreaks in the same 
institution between 1977 and 1982. Sapoviruses play an important role in outbreaks of gastroenteritis in infants and 
have recently been found to infect adults. 
Source:  Dorland’s illustrated medical dictionary, 31st ed. Philadelphia: Saunders/Elsevier; 2007; Chiba S, Nakata S, Numata-
Kinoshita K, Honma S. Sapporo virus: history and recent ﬁ  ndings. J Infect Dis. 2000;181(Suppl 2):S303–8.